Adiponectin and Risk of Stroke: Prospective Study and Meta-analysis
Overview
Neurology
Authors
Affiliations
Background And Purpose: The favorable cardiovascular effects attributed to adiponectin may lower risk of stroke. We investigated this in a prospective study and meta-analysis.
Methods: A case-cohort study nested within the Potsdam cohort of the European Prospective Investigation into Cancer was performed, with 170 incident cases of ischemic stroke and a randomly selected subcohort of 2155 participants without major cardiovascular disease at baseline. A random-effects dose-response meta-analysis was performed on prospective studies reporting on adiponectin and incident stroke in healthy populations up to April 2013, identified through MEDLINE and EMBASE.
Results: In European Prospective Investigation into Cancer-Potsdam, after adjustment for cardiovascular risk factors, the hazard ratio of ischemic stroke per 5-µg/mL higher total-adiponectin was 1.10 (95% confidence interval, 0.89-1.37). Participants with higher total-adiponectin had higher high-density lipoprotein-cholesterol and lower high-sensitivity C-reactive protein and triglyceride levels, and had less often diabetes mellitus. Additional adjustment for these putative mediators yielded a hazard ratio of 1.31 (95% confidence interval, 1.04-1.64). Nine studies (19,259 participants, 2960 cases), including European Prospective Investigation into Cancer-Potsdam, were meta-analyzed. Pooling relative risks adjusted for cardiovascular risk factors not including putative mediators indicated moderate between-study heterogeneity (I2=52.2%). This was explained by the smallest study, and the pooled relative risk (95% confidence interval) before and after its exclusion was 1.03 (0.98-1.08) and 0.99 (0.96-1.01) per 5 µg/mL, respectively. The pooled relative risk (95% confidence interval) additionally adjusted for potential mediators was 1.08 (1.01-1.15) and 1.05 (1.00-1.11) before and after excluding the same study, respectively.
Conclusions: Adiponectin is not associated with risk of stroke. If anything, adiponectin relates directly to stroke risk after controlling for risk factors that favorably correlate with adiponectin.
Castanon-Apilanez M, Garcia-Cabo C, Martin-Martin C, Prieto B, Cernuda-Morollon E, Rodriguez-Gonzalez P Nutrients. 2024; 16(18).
PMID: 39339817 PMC: 11435288. DOI: 10.3390/nu16183218.
Xiang B, Huo Y, Zhong P, Wang C, Wu X, Zhao J Noro Psikiyatr Ars. 2024; 67(3):281-288.
PMID: 39258125 PMC: 11382555. DOI: 10.29399/npa.28485.
Zaharia A, Oprea V, Coada C, Tanase C, Ionescu A, Chirila S Biomedicines. 2024; 12(8).
PMID: 39200292 PMC: 11351472. DOI: 10.3390/biomedicines12081828.
The Role of Adipokines in Health and Disease.
Clemente-Suarez V, Redondo-Florez L, Beltran-Velasco A, Martin-Rodriguez A, Martinez-Guardado I, Navarro-Jimenez E Biomedicines. 2023; 11(5).
PMID: 37238961 PMC: 10216288. DOI: 10.3390/biomedicines11051290.
Obesity and the risk of cardiometabolic diseases.
Valenzuela P, Carrera-Bastos P, Castillo-Garcia A, Lieberman D, Santos-Lozano A, Lucia A Nat Rev Cardiol. 2023; 20(7):475-494.
PMID: 36927772 DOI: 10.1038/s41569-023-00847-5.